Keywords: Phantoms, Spectroscopy, 2HG, phantom, brain tumor, glioma
Motivation: The GlioGuard phantom was developed to address the challenges in achieving accurate, reproducible 2HG measurements enabling optimization of MRS sequences and validation of basis sets for glioma diagnostics.
Goal(s): To evaluate GlioGuard’s capability of measuring 2HG concentrations accurately by comparing optimized MRS sequences; PRESS and sLASER.
Approach: GlioGuard used increasing 2HG concentrations in BRAINO solution, where the experiment was repeated with more Clariscan. MRS data from PRESS and sLASER sequences were acquired on a 3T scanner at Haukeland University Hospital. Data analysis involved metabolite quantification using Osprey [1].
Results: sLASER provided more reproducible measurements, suggesting higher robustness for 2HG detection in clinical QA.
Impact: GlioGuard standardizes 2HG detection in MRS, improving reliability and clinical relevance for glioma diagnostics. It provides cost-efficient, tumor-relevant compartments for accurate metabolite quantification, benefiting facilities without established MRS protocols or facilities focusing on optimization and quality assurance (QA).
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords